Familial hypercholesterolaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PCSK9 14
• APOE 1
• PPAR 0
• ANGPTL3 3
• CD40 0
• AMPK 0
• MAPK 0
• TP53 0
• NRF2 0
• TNF 0
• BCL-2 0
• ERK 0
• mTOR 0
• NLRP3 1
• ALK 0
• EGFR 0
• GLP-1 1
• HER2 0
• IL-6 0
• JNK 0
• SIRT1 0
• STAT3 0
• STING 0
• YAP 0
• BDNF 0
• BRCA1 0
• BRCA2 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0
• HMGB1 0
• IL-17 0
• JAK 0
• KRAS 0
• LAG-3 0
• MDM2 0
• MEK 0
• PD-L1 0
• PSMA 0
• ROS1 0
• TLR4 0
• VEGF 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · F31

  Examining Real-World Uptake and Effectiveness of GLP-1 RA in an Urban Population with Type-2 Diabetes

  New York University School of Medicine· New York, United States· US$36,947 awarded in fiscal year 2026· until Sept 2028

• NIH NIDDK · F32

  Biomarkers for Thrombotic Risk Stratification in Nephrotic Syndrome

  Children's Hosp of Philadelphia· Philadelphia, United States· US$86,824 awarded in fiscal year 2026· until Sept 2027

• NIH NHLBI · R01

  Regulation of vascular smooth muscle phenotype by TEADs

  Louisiana State Univ Hsc Shreveport· Shreveport, United States· US$708,741 awarded in fiscal year 2026· until May 2030

• NIH NIA · F30

  Defining immune checkpoints during cysteine restriction that limits age related atherosclerosis

  Yale University· New Haven, United States· US$55,114 awarded in fiscal year 2026· until Sept 2030

• NIH NHLBI · R21

  Integrative Dissection of the Genetic Basis for Lipid Subfractions Across Age Groups and Environment

  Pennsylvania State Univ Hershey Med Ctr· Hershey, United States· US$254,021 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  NEW STRATEGIES FOR THE EARLY DIAGNOSIS, RISK STRATIFICATION AND CO-MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA (FH-EARLY)

  Associação para Investigação e Desenvolvimento da Faculdade de Medicina· Lisbon, Portugal· EU contribution €7,286,252· until Dec 2028· 9 countries

6 of 246 running projects, newest first. Listed amounts together: US$169.2m + €7.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 7
• Gene Expression Profiling 15
• Whole Genome Sequencing 4
• Exome Sequencing 11
• Proteomics 6
• Metabolomics 5
• Mass Spectrometry 5
• Flow Cytometry 13
• Immunohistochemistry 18
• Xenograft Model Antitumor Assays 8
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 18
• Machine Learning 7
• Cohort Studies 75
• Genome-Wide Association Study 8

• Aortic Stenosis Hyalectan Remodeling Revealed by Proteomics and Glycoproteomics.

  Arterioscler Thromb Vasc Biol, Jul 2026

• Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study.

  Proteomics Clin Appl, May 2026

• An In Vitro Functional Characterization of the Cholesterol-Transforming Blautia hominis Strain HA2291 Isolated from the Human Gut.

  Nutrients, Mar 2026

• Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia.

  J Clin Lipidol, Apr 2017

• Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity.

  Proteomics, Apr 2013

• Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells.

  J Proteome Res, Oct 2011

See which targets of this disease your abstract mentions, and go to the people working on them.